Landau theory of bi-criticality in a random quantum rotor system

We consider here a generalization of the random quantum rotor model in which each rotor is characterized by an M-component vector spin. We focus entirely on the case not considered previously, namely when the distribution of exchange interactions has non-zero mean. Inclusion of non-zero mean permits ferromagnetic and superconducting phases for M=1 and M=2, respectively. We find that quite generally, the Landau theory for this system can be recast as a zero-mean problem in the presence of a magnetic field. Naturally then, we find that a Gabay-Toulouse line exists for $M>1$ when the distribution of exchange interactions has non-zero mean. The solution to the saddle point equations is presented in the vicinity of the bi-critical point characterized by the intersection of the ferromagnetic (M=1) or superconducting (M=2) phase with the paramagnetic and spin glass phases. All transitions are observed to be second order. At zero temperature, we find that the ferromagnetic order parameter is non-analytic in the parameter that controls the paramagnet/ferromagnet transition in the absence of disorder. Also for M=1, we find that replica symmetry breaking is present but vanishes at low temperatures. In addition, at finite temperature, we find that the qualitative features of the phase diagram, for M=1, are {\it identical} to what is observed experimentally in the random magnetic alloy $LiHo_xY_{1-x}F_4$.Comment: 20 pages, 5 figure

Association of C-reactive protein and metabolic risk with cognitive effects of lurasidone in patients with schizophrenia

BACKGROUND: Accumulating evidence has implicated insulin resistance and inflammation in the pathophysiology of cognitive impairments associated with neuropsychiatric disorders. This post-hoc analysis based on a placebo-controlled trial investigated the effect of inflammation (indexed by CRP) and metabolic risk factors on cognitive performance in patients with schizophrenia treated with lurasidone. METHODS: Acutely exacerbated patients with schizophrenia were randomized to lurasidone (80 or 160 mg/day), quetiapine XR 600 mg/day, or placebo. A wide range CRP test and a cognitive assessment using the CogState computerized battery were performed at baseline and week 6 study endpoint. Associations between log-transformed CRP, high density lipoprotein (HDL), homeostatic model assessment of insulin resistance (HOMA-IR) and treatment response were evaluated. RESULTS: CRP combined with HDL, triglyceride-to-HDL (TG/HDL) ratio, or HOMA-IR at study baseline were significant moderators of the improvement in cognitive performance associated with lurasidone 160 mg/day (vs. placebo) treatment (p \u3c .05). Greater placebo-corrected treatment effect size on the CogState composite score was observed for patients in the lurasidone 160 mg/day treatment group who had either low CRP and high HDL (d = 0.43), or low CRP and low HOMA-IR (d = 0.46). Interactive relationships between CRP, HDL, TG/HDL, HOMA-IR and the antipsychotic efficacy of lurasidone or quetiapine XR were not significant. There were no significant associations between antipsychotic treatment and changes in CRP level at study endpoint. CONCLUSIONS: Findings of this post-hoc analysis based on a placebo-controlled trial in patients with schizophrenia suggest that baseline CRP level combined with measures of metabolic risk significantly moderated the improvement in cognitive performance associated with lurasidone 160 mg/day (vs. placebo) treatment. Our findings underscore the importance of maintaining a low metabolic risk profile in patients with schizophrenia

Ten Simple Rules for Getting Help from Online Scientific Communities

The increasing complexity of research requires scientists to work at the intersection of multiple fields and to face problems for which their formal education has not prepared them. For example, biologists with no or little background in programming are now often using complex scripts to handle the results from their experiments; vice versa, programmers wishing to enter the world of bioinformatics must know about biochemistry, genetics, and other fields. In this context, communication tools such as mailing lists, web forums, and online communities acquire increasing importance. These tools permit scientists to quickly contact people skilled in a specialized field. A question posed properly to the right online scientific community can help in solving difficult problems, often faster than screening literature or writing to publication authors. The growth of active online scientific communities, such as those listed in Table S1, demonstrates how these tools are becoming an important source of support for an increasing number of researchers. Nevertheless, making proper use of these resources is not easy. Adhering to the social norms of World Wide Web communication—loosely termed “netiquette”—is both important and non-trivial. In this article, we take inspiration from our experience on Internet-shared scientific knowledge, and from similar documents such as “Asking the Questions the Smart Way” and “Getting Answers”, to provide guidelines and suggestions on how to use online communities to solve scientific problems

Chandra Detections of Two Quiescent Black Hole X-Ray Transients

Using the Chandra X-ray Observatory, we have detected the black hole transients V4641 Sgr and XTE J1859+226 in their low luminosity, quiescent states. The 0.3-8 keV luminosities are (4.0^(+3.3)_(-2.4))E31 (d/7 kpc)^2 erg/s and (4.2^(+4.8)_(-2.2))E31 (d/11 kpc)^2 erg/s for V4641 Sgr and XTE J1859+226, respectively. With the addition of these 2 systems, 14 out of the 15 transients with confirmed black holes (via compact object mass measurements) now have measured quiescent luminosities or sensitive upper limits. The only exception is GRS 1915+105, which has not been in quiescence since its discovery in 1992. The luminosities for V4641 Sgr and XTE J1859+226 are consistent with the median luminosity of 2E31 erg/s for the systems with previous detections. Our analysis suggests that the quiescent X-ray spectrum of V4641 Sgr is harder than for the other systems in this group, but, due to the low statistical quality of the spectrum, it is not clear if V4641 Sgr is intrinsically hard or if the column density is higher than the interstellar value. Focusing on V4641 Sgr, we compare our results to theoretical models for X-ray emission from black holes in quiescence. Also, we obtain precise X-ray positions for V4641 Sgr and XTE J1859+226 via cross-correlation of the X-ray sources detected near our targets with IR sources in the 2 Micron All-Sky Survey catalog.Comment: 4 pages, Accepted by ApJ Letter

Clinical Outcomes of Molecular Tumor Boards: A Systematic Review

PURPOSE: We conducted this systematic review to evaluate the clinical outcomes associated with molecular tumor board (MTB) review in patients with cancer. METHODS: A systematic search of PubMed was performed to identify studies reporting clinical outcomes in patients with cancer who were reviewed by an MTB. To be included, studies had to report clinical outcomes, including clinical benefit, response, progression-free survival, or overall survival. Two reviewers independently selected studies and assessed quality with the Quality Assessment Tool for Before-After (Pre-Post) Studies with No Control Group or the Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies depending on the type of study being reviewed. RESULTS: Fourteen studies were included with a total of 3,328 patients with cancer. All studies included patients without standard-of-care treatment options and usually with multiple prior lines of therapy. In studies reporting response rates, patients receiving MTB-recommended therapy had overall response rates ranging from 0% to 67%. In the only trial powered on clinical outcome and including a control group, the group receiving MTB-recommended therapy had significantly improved rate of progression-free survival compared with those receiving conventional therapy. CONCLUSION: Although data quality is limited by a lack of prospective randomized controlled trials, MTBs appear to improve clinical outcomes for patients with cancer. Future research should concentrate on prospective trials and standardization of approach and outcomes